.jpg?format=webp&width=780)
A study revealed that avacopan brings significant enhancements to health-related quality of life and utility scores in patients with ANCA-associated vasculitis. The study enrolled 331 patients and demonstrated avacopan's superiority over standard prednisone treatment at both 26 and 52 weeks. Patients on avacopan reported noteworthy improvements in physical well-being and health utilities, with the potential to reduce prednisone doses.
Like
Save
Share